Article
Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol.
BMJ open - 1 Oct 2020
Monserrat Villatoro Jaime, García García Irene, Bueno David, de la Cámara Rafael, Estébanez Miriam, López de la Guía Ana, Abad-Santos Francisco, Antón Cristina, Mejía Gina, Otero María José, Ramírez García Elena, Frías Iniesta Jesús, Carcas Antonio, Borobia Alberto M
Abstract excerpt
INTRODUCTION: Invasive aspergillosis is the most important cause of morbidity and mortality in patients with haematological diseases. At present, voriconazole is the first-line treatment for invasive fungal disease. The pharmacokinetic interindividual variability of voriconazole depends on genetic factors. CYP450 is involved in 70%-75% of total metabolism of voriconazole, mainly CYP3A4 and CYP2C19, with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.